THE INFLUENCE OF RESISTIN ON LIPID METABOLISM IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH NORMAL BODY WEIGHT AND OBESITY
Abstract
It were examined 70 patients with non-alcoholic fatty liver disease and its combination with obesity, as well as 20 healthy individuals. The study was carried out using the following methods: clinical, laboratory and instrumental (including liver biopsy). It was found an inverse relationship between the level of resistin and the levels of the indices of lipid metabolism in both groups of patients. There was established the significant increase of plasma level of resistin, and also impairment of lipid metabolism indices in all groups in comparison with the controls, and most pronounced changes in patients with NAFLD and obesity. The established relationships suggests that the increase resistin may represent the presence of dyslipidemia in patients with NAFLD and its combination with obesity. In order to determination the disorder of the lipid metabolism is recommended to determine the level of resistin in patients with NAFLD, especially in presence of obesity. Patients with the level of resistin (>8,06±0,23 ng/ml) should refer to the risk of progression of dyslipidemia.
About the Authors
L. V. Zhuravlyova
Kharkiv National Medical University
Russian Federation
Russian Federation
E. V. Ogneva
Kharkiv National Medical University
Russian Federation
Russian Federation
References
1. Харченко Н. В. Неалкогольная жировая болезнь печени: терапевтические возможности L-карнитина. Н. В. Харченко. Гепатология, тематичний номер, 2017, с. 28.
2. Христич Т. Н. Значимость гормонов висцеральной жировой ткани в развитии коморбидности хронического панкреатита и ожирения. Вестник клуба пакреатологов, 2017, № 3 (36), сс. 30-32.
3. Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012, Vol. 55, рр. 2005-2023.
4. Codoner-Franch P, Alonso-Iglesias E. Resistin: insulin resistance to malignancy. Clin Chim Acta, 2015, Vol. 438, рр. 46-54.
5. Costandi J, Melone M, Zhao A, Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ Res., 2011, Vol. 108, рр. 727-742.
6. Dalamaga M. Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives. Biomark Med., 2014, Vol. 8, № 1, рр. 107-118
7. ЕASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016, http://dx.doi.org/10.1016/j.jhep.2015.11.004
8. Huang X, Yang Z. Resistin’s, obesity and insulin resistance: the continuing disconnect between rodents and humans. J Endocrinol Invest, 2016, Vol. 39, рр. 607-615.
9. Sahu A. Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol, 2003, Vol. 24, № 4, рр. 225-253.
10. Ståi P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol, 2015, Vol.21(39), рр. 11077-110.
Review
For citations:
Zhuravlyova L.V., Ogneva E.V. THE INFLUENCE OF RESISTIN ON LIPID METABOLISM IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH NORMAL BODY WEIGHT AND OBESITY. Experimental and Clinical Gastroenterology. 2018;(2):19-23. (In Russ.)
Views:
337
Email this article 